Edegem

• MyKid-study: a study to examine the effect and safety of an injection of Mydrane® into the eye of children who will undergo cataract surgery Ended
  2023-504173-21-00 6 2023-07-01 pediatric cataract
• Phase 1 Study of BMS-986416 with and without Nivolumab in Solid Tumors Ended
  2022-501317-31-00 2 2023-06-29 Solid tumor
• Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants Ended
  2023-504461-23-00 3 2023-06-26 Fibrostenotic Crohn’s disease
• A study to test how well different doses of BI 1815368 are tolerated by healthy men Ended
  2023-503815-13-00 3 2023-06-19 Healthy
• First-in-human study of SAR445611 in healthy adult participants Ended
  2022-502923-23-00 1 2023-06-12 Immune system diseases
• A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended
  2022-500101-41-00 6 2023-06-07 Type 2 Diabetes
• A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tab … Ended
  2022-502814-99-00 2 2023-05-30 Non-small cell lung cancer (NSCLC)
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th … Ended
  2022-500121-33-01 5 2023-05-08 Anti-GBM antibody disease (Goodpasture disease)
• A study to find and confirm the dose and assess the safety, reactogenicity and immune response of a vaccine against influenza in healthy you … Ended
  2022-502308-66-00 7 2023-04-27 Healthy volunteers (prevention of influenza infection)
• A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended
  2023-506352-24-00 5 2023-04-13 Non-obstructive Hypertrophic Cardiomyopathy
• INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies Ended
  2022-501505-13-00 1 2023-03-31 Metastatic melanoma
• Phase 2b Study of GSK4532990 in Adults with NASH (HORIZON) Ended
  2023-507503-62-00 4 2023-03-30 Non-alcoholic Fatty Liver Disease
• Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE) Ended
  2023-510144-20-00 9 2023-03-29 Advanced Systemic Mastocytosis
• A clinical study to evaluate a new medicinal product VS-01 in patients with an acute episode on top of a chronic liver disease (called acute … Ended
  2024-513706-56-00 4 2023-03-22 Acute-on-chronic liver failure (ACLF) is characterized by hepatic and
• A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended
  2024-511089-36-00 4 2023-03-17 Crohn’s disease
• Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose. Ended
  2023-510195-31-00 4 2023-01-03 Idiopathic or Diabetic Gastroparesis
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended
  2023-508528-36-00 5 2022-12-16 Resected squamous cell carcinoma of the head and neck
• A study to test whether BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder Ended
  2023-506369-79-00 4 2022-11-30 Pancreatic ductal adenocarcinoma
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• A study to test the safety of MK-1654 and how well MK-1654 works in healthy infants Ended
  2022-500350-42-01 10 2022-11-07 Prevention of RSV
• A study to test trimodulin in adult hospitalized patients with CAP including COVID-19 pneumonia. Ended
  2024-513002-60-00 5 2022-10-26 Non-severe community-acquired pneumonia (CAP) or moderate or severe Co
• Zibotentan and Dapagliflozin combination, Evaluated in Liver cirrhosis (ZEAL study) Ended
  2023-505405-17-00 4 2022-10-07 Liver cirrhosis with features of portal hypertension.
• A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors Ended
  2023-508280-69-00 1 2022-10-07 Advanced Malignant Tumors
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio

Showing 505–528 of 583 trials